XETRA - Delayed Quote EUR

Amgen Inc. (AMG.DE)

257.50

+1.60

+(0.63%)

At close: June 13 at 5:35:44 PM GMT+2

BMY Focuses on Label Expansion of Drugs: Will This Revive Growth?

BMY's banks on label expansion of drugs like Sotyktu and Opdivo to boost sales in the wake of generic competition for legacy drugs.

Zacks 15 hours ago

CELG-RT

AMGN
Amgen (NASDAQ:AMGN) Has A Pretty Healthy Balance Sheet

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Simply Wall St. 15 hours ago

AMGN
AMGEN AND FOOTBALL LEGEND BARRY SANDERS HIGHLIGHT DANGERS OF BAD CHOLESTEROL IN NEW DOCUMENTARY

Amgen (NASDAQ: AMGN) today announced the launch of The Making of a Heart Attack, a documentary that sheds light on the cardiovascular disease crisis in the United States, where every 40 seconds someone has a heart attack or stroke.1

PR Newswire 15 hours ago

AMGN
Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider

Amgen (AMGN) closed at $297.29 in the latest trading session, marking a +1.88% move from the prior day.

Zacks yesterday

AMGN
Here's Why Amgen (AMGN) is a Strong Momentum Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks 2 days ago

AMGN
Why Amgen (AMGN) is a Top Growth Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks 3 days ago

AMGN
Why Amgen (AMGN) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks 4 days ago

AMGN
3 Generic Drug Stocks to Watch Amid Pricing Pressure & Tariff Threats

Sandoz, Teva and Viatris are navigating generic drug pricing pressure with scale, complex generics and cost cuts.

Zacks 4 days ago

TEVA

VTRS

AMGN
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.

Zacks 4 days ago

AMGN
The Next Look At Amgen's Obesity Drug Is Coming. Here's What Investors Are Watching.

Later this month, the Street will have a fresh opportunity to gauge the potential for Amgen's experimental weight-loss drug, MariTide.

Investor's Business Daily 7 days ago

NONOF

NVO

AMGN
2 Dividend Growth Stocks to Buy and Hold Forever

Novartis and Amgen also boast impeccable dividend track records, which should please investors. Let's consider two examples in the healthcare sector: Amgen (NASDAQ: AMGN) and Novartis (NYSE: NVS). Amgen's organic revenue hasn't always grown as fast as Wall Street would have wanted over the past few years.

Motley Fool 7 days ago

NVS

AMGN
AMGEN TO PRESENT AT GOLDMAN SACHS 46TH ANNUAL GLOBAL HEALTHCARE CONFERENCE

Amgen (NASDAQ: AMGN) will present at the Goldman Sachs 46th Annual Global Healthcare Conference at 9:20 a.m. PT on Tuesday, June 10, 2025. Peter Griffith, executive vice president and chief financial officer at Amgen, and Jay Bradner, executive vice president of Research and Development at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

PR Newswire 8 days ago

AMGN
RDY & ALVO Ink Collaboration Deal for Merck's Keytruda Biosimilar

Dr. Reddy teams up with Alvotech to co-develop and commercialize a biosimilar of MRK's Keytruda, aiming to expand its biosimilars footprint.

Zacks 8 days ago

AMGN
Profit From the Silver Tsunami: Must-Watch Senior Care & Aging Stocks

BSX, ABBV, AMGN and DXCM are tapping into the aging boom with cutting-edge tech, chronic care drugs and senior-focused innovations.

Zacks 9 days ago

ABBV

AMGN

DXCM
ASCO 2025: DeLLphi-304 helps Amgen to pave the way for BiTEs in solid cancers

Imdelltra is a BiTE that targets DLL3 and CD3 receptors.

Clinical Trials Arena 9 days ago

AMGN
Amgen's Imdelltra Cuts Lung Cancer Death Risk by 40% in Phase III

AMGN's Imdelltra slashes lung cancer death risk by 40% in Phase III, extending survival by over five months compared to chemotherapy.

Zacks 10 days ago

AMGN
Amgen Says Imdelltra Reduced Death Risk by 40% in Small Cell Lung Cancer Trial

Amgen (AMGN) said Monday its Imdelltra drug lowered the risk of death by 40% compared to standard ch

PREMIUM
MT Newswires 11 days ago

AMGN
ASCO25: Amgen’s Nplate proves effective in GI cancer-linked thrombocytopaenia

Nplate improved platelet response and reduced therapy modification for patients with chemotherapy-induced thrombocytopaenia.

Clinical Trials Arena 11 days ago

AMGN

GLDAF
Amgen (NasdaqGS:AMGN) Announces Positive Results From Phase 3 Lung Cancer Trial

Amgen (NasdaqGS:AMGN) recently announced interim results from its Phase 3 DeLLphi-304 trial for IMDELLTRA, showing significant improvement in survival outcomes for SCLC patients. This announcement coincided with a 6% rise in the company's stock last week. This gain aligns with the broader market trend, as the market also posted gains recently, despite minor fluctuations due to ongoing China-U.S. trade tensions. The promising clinical trial results likely provided additional positive sentiment...

Simply Wall St. 11 days ago

AMGN
IMDELLTRA® SIGNIFICANTLY REDUCED RISK OF DEATH BY 40% IN SMALL CELL LUNG CANCER PATIENTS

Amgen (NASDAQ:AMGN) today announced new interim results from the global Phase 3 DeLLphi-304 trial showing IMDELLTRA® (tarlatamab-dlle) reduced the risk of death by 40% and significantly extended median overall survival (OS) by more than five months compared to standard-of-care (SOC) chemotherapy in patients with small cell lung cancer (SCLC) who progressed on or after one line of platinum-based chemotherapy (median OS: 13.6 vs 8.3 months; hazard ratio [HR], 0.60; 95% confidence interval [CI]: 0.

PR Newswire 11 days ago

AMGN

Performance Overview

Return	AMG.DE	S&P 500 (^GSPC)
YTD	+3.94%	+1.62%
1-Year	-3.66%	+10.00%
3-Year	+24.71%	+59.40%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Amgen Inc. (AMG.DE)

BMY Focuses on Label Expansion of Drugs: Will This Revive Growth?

Amgen (NASDAQ:AMGN) Has A Pretty Healthy Balance Sheet

AMGEN AND FOOTBALL LEGEND BARRY SANDERS HIGHLIGHT DANGERS OF BAD CHOLESTEROL IN NEW DOCUMENTARY

Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider

Here's Why Amgen (AMGN) is a Strong Momentum Stock

Why Amgen (AMGN) is a Top Growth Stock for the Long-Term

Why Amgen (AMGN) is a Top Value Stock for the Long-Term

3 Generic Drug Stocks to Watch Amid Pricing Pressure & Tariff Threats

Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It

The Next Look At Amgen's Obesity Drug Is Coming. Here's What Investors Are Watching.

2 Dividend Growth Stocks to Buy and Hold Forever

AMGEN TO PRESENT AT GOLDMAN SACHS 46TH ANNUAL GLOBAL HEALTHCARE CONFERENCE

RDY & ALVO Ink Collaboration Deal for Merck's Keytruda Biosimilar

Profit From the Silver Tsunami: Must-Watch Senior Care & Aging Stocks

ASCO 2025: DeLLphi-304 helps Amgen to pave the way for BiTEs in solid cancers

Amgen's Imdelltra Cuts Lung Cancer Death Risk by 40% in Phase III

Amgen Says Imdelltra Reduced Death Risk by 40% in Small Cell Lung Cancer Trial

ASCO25: Amgen’s Nplate proves effective in GI cancer-linked thrombocytopaenia

Amgen (NasdaqGS:AMGN) Announces Positive Results From Phase 3 Lung Cancer Trial

IMDELLTRA® SIGNIFICANTLY REDUCED RISK OF DEATH BY 40% IN SMALL CELL LUNG CANCER PATIENTS

Performance Overview